LICENSE AGREEMENTLicense Agreement • November 13th, 2023 • 1427702 B.C. LTD • Pharmaceutical preparations • British Columbia
This Agreement (“Agreement”) is effective as of this ____ day of _____________ 2022, (“Effective Date”) between FILAMENT HEALTH CORP. a British Columbia corporation, with offices at #210-4475 Wayburne Drive, Burnaby BC V5G4X4 (“Filament”) and PSYENCE BIOMED CORP, a corporation organized under the laws of British Columbia with an address at 200 Bay Street, Suite 2010 Toronto, Ontario, Canada M5J 2J1 (“Psyence”). Filament and Psyence may be referred to herein singularly as a “party” and collectively as the “parties”.
ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENTAssignment, Assumption and Amendment Agreement • November 7th, 2023 • 1427702 B.C. LTD • Pharmaceutical preparations • New York
This Assignment, Assumption and Amendment Agreement (this “Agreement”) is made as of [●], 2023, by and among Jupiter Acquisition Corporation, a Delaware corporation (“Jupiter”), 1427702 B.C. Ltd., a corporation organized under the laws of British Columbia (the “Company”), and Continental Stock Transfer & Trust Company, a New York limited purpose trust company, as warrant agent (the “Warrant Agent”).
STOCKHOLDERS’ RIGHTS AGREEMENTStockholders’ Rights Agreement • September 22nd, 2023 • 1427702 B.C. LTD • Pharmaceutical preparations • Delaware
THIS STOCKHOLDERS’ RIGHTS AGREEMENT (this “Agreement”), is entered into and effective as of January 9, 2023 (the “Effective Date”), by and among Magdalena Biosciences Inc., a Delaware corporation (the “Company”), and each holder of the Common Stock of the Company (as defined below) listed on Schedule A (collectively, the “Stockholders”).
LICENSE AGREEMENTLicense Agreement • October 16th, 2023 • 1427702 B.C. LTD • Pharmaceutical preparations • British Columbia
This Agreement (“Agreement”) is effective as of this 18th day of April 2022, (“Effective Date”) between FILAMENT HEALTH CORP. a British Columbia corporation, with offices at #210-4475 Wayburne Drive, Burnaby BC V5G4X4 (“Filament”) and PSYENCE BIOMED CORP, a corporation organized under the laws of British Columbia with an address at 200 Bay Street, Suite 2010 Toronto, Ontario, Canada M5J 2J1 (“Psyence”). Filament and Psyence may be referred to herein singularly as a “party” and collectively as the “parties”.
LICENSE AND SUPPLY AGREEMENTLicense and Supply Agreement • October 16th, 2023 • 1427702 B.C. LTD • Pharmaceutical preparations • Delaware
This License and Supply License and Supply Agreement (“Agreement”) is effective as of this 22 day of August 2023, (“Effective Date”) between FILAMENT HEALTH CORP. a British Columbia corporation, with offices at #210-4475 Wayburne Drive, Burnaby BC V5G4X4 (“Filament”) and RESET PHARMACEUTICALS, INC., a Delaware corporation having a principal place of business at 98 Cuttermilk Road, Suite 486, Great Neck, NY 11021, USA, (“Reset Pharma”). Filament and Reset Pharma may be referred to herein singularly as a “party” and collectively as the “parties”.
VOTING AGREEMENTAdoption Agreement • September 22nd, 2023 • 1427702 B.C. LTD • Pharmaceutical preparations • Delaware
THIS VOTING AGREEMENT (this “Agreement”) is effective as of January 9, 2023 (the “Effective Date”), by and among Magdalena Biosciences Inc., a Delaware corporation (the “Company”) and each holder of the Voting Common Stock of the Company (as defined below) listed on Schedule A (collectively, the “Stockholders”).
SERVICES AGREEMENTServices Agreement • September 22nd, 2023 • 1427702 B.C. LTD • Pharmaceutical preparations • Delaware
This SERVICES AGREEMENT (this “Agreement”) is made effective as of January 9, 2023 (the “Effective Date”) by and between Filament Health Corp., a Vancouver, B.C. corporation (the “Provider”), and Magdalena Biosciences Inc., a Delaware corporation (the “Company”). Provider and Company are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
LICENCE AGREEMENTLicence Agreement • October 16th, 2023 • 1427702 B.C. LTD • Pharmaceutical preparations • British Columbia
This Agreement (“Agreement”) is effective as of this 27th day of June 2023, (“Effective Date”) between FILAMENT HEALTH CORP. a British Columbia corporation, with offices at #210-4475 Wayburne Drive, Burnaby BC V5G4X4 (“Filament”) and NeoLumina Bioscience Inc., a British Columbia corporation having a principal place of business at 7860 Venture St, Burnaby, BC, V5A 3A2 (“NeoLumina”). Filament and NeoLumina may be referred to herein singularly as a “Party” and collectively as the “Parties”.
